Lung Cancer: Five Things You Need to Know

More than 228,000 new cases of lung cancer will be diagnosed in the United States in 2013, according to the National Cancer Institute (NCI). With November marking Lung Cancer Awareness Month, Pasi A. Jänne, MD, PhD, director of Dana-Farber’s Lowe Center for Thoracic Oncology, answers some key questions about the disease:

Infographic: Breast Cancer and Genetics

Breast cancer is the most common cancer among American women, but only 5-10 percent of breast cancer cases are hereditary. Of those cases, roughly 20-25 percent are linked to mutations in the BRCA1 and BRCA2 genes (BRCA stands for BReast CAncer susceptibility). View the infographic below for more on the genetics of breast cancer.

Video: Nearly 100 Patients Inspire Others with Stories of Hope

Each year, Dana-Farber patients join clinicians, staff, and the Boston Red Sox to share their stories of inspiration and their belief in the research advances at Dana-Farber during the WEEI/NESN Jimmy Fund Radio-Telethon at Fenway Park. This year, nearly 100 patients, including Rayquan Fregeau, who used art and resources from the Betty Ann Blum and Marjorie Blum Pediatric Resource Room to cope with his diagnosis; Debbie Whitmore, a mother of five who hopes for a cure for future generations; and Jack Robinson, who compiled a joke book to help other children during their treatment, shared their experiences battling cancer. Stephen …

Continue reading

Ask the Expert: Questions and Answers about Brain Tumors

Dana-Farber Cancer Institute recently partnered with CancerConnect and Lakshmi Nayak, MD, to answer questions about brain cancer. Nayak is a neuro-oncologist in the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center and an instructor in neurology at Harvard Medical School.  Q: There seems to be some progress concerning treatment of brain tumors, especially immunotherapy. Do you think we will see further advancements in that area, or in other areas? A: Immunotherapy is indeed a hot topic in gliomas. This is largely driven by advances we have seen in the treatment of melanoma. The way these drugs work is to …

Continue reading

Targeting Triple-Negative Breast Cancer

Breast cancer may develop in one part of the body, but it’s not just one disease. In fact, oncologists think of breast cancer as at least three different types of diseases. Triple-negative breast cancer (TNBC) describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors. It makes up approximately 15 percent of all breast cancers and is typically more aggressive than the other two types, estrogen receptor-positive breast cancer and HER2-positive breast cancer. “It may be the smallest group, but TNBC still represents thousands of women with breast cancer, so it is a very important group for …

Continue reading

Study: Type of Cervical Cancer May Drive Treatment Choice

By Alexi Wright, MD, MPH Although there are two main types of cervical cancer, known as adenocarcinoma and squamous cell carcinoma, they’ve generally been treated as one disease, with the same approach to treatment. In a recent study, my colleagues and I surveyed the DNA in both types of cervical cancer cells to see if there were any differences. Such variations may help explain why the two types sometimes behave the way they do, and guide us toward treatments that work best in one type or the other.

What is Personalized Medicine?

By Richard Saltus Physicians have long recognized that the same disease can behave differently from one patient to another, and that there is no one-size-fits-all treatment. In cancer, chemotherapy might dramatically shrink one lung tumor but prove ineffective against the same type of tumor in a different patient – even though tissue samples look identical under the microscope. Side effects and appropriate dosage may vary from patient to patient as well. The goal of personalized medicine is to match a treatment to the unique characteristics of an individual patient: his or her personal and family medical history, age, body size, and …

Continue reading

Ask the Expert: Questions and Answers about Ovarian Cancer

Dana-Farber Cancer Institute recently partnered with CancerConnect and Ursula Matulonis, MD, to answer questions about ovarian cancer. Experts in the Susan F. Smith Center for Women’s Cancers offer the latest research and treatment for this type of cancer. Watch one patient’s story. Q: Is taking curcumin recommended to prevent ovarian cancer from returning? Do you have any other suggestions for preventing recurrence?

Research in Advanced Ovarian Cancer Shows Promise

By Ursula Matulonis, MD After a long period of slow progress, new knowledge about the genetics of ovarian cancer is leading to the development and testing of new therapies. Researchers at the Susan F. Smith Center for Women’s Cancers will soon be launching several phase 3 clinical trials testing drugs known as PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer – tumors that initially responded to platinum-based chemotherapy agents but have shown evidence of regrowth at least six months after treatment. Phase 3 trials test drugs in large numbers of patients to evaluate the drugs’ effectiveness as well as …

Continue reading